More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$16.71B
EPS
3.35
P/E ratio
18.7
Price to sales
6.09
Dividend yield
--
Beta
0.454266
Previous close
$67.10
Today's open
$66.75
Day's range
$66.26 - $68.54
52 week range
$39.71 - $73.69
show more
CEO
Michael M. Morrissey
Employees
1077
Headquarters
Alameda, CA
Exchange
Nasdaq Global Select
Shares outstanding
244010895
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Exelixis, Inc. (EXEL) Presents at UBS Global Biopharma Conference 2026 Transcript
Exelixis, Inc. (EXEL) Presents at UBS Global Biopharma Conference 2026 Transcript
Seeking Alpha • Nov 17, 2026

Where Will Exelixis Be in 5 Years? 1 Experimental Drug Could Change Everything
Cabometyx's sales keep growing, but generic competition looms by the end of the decade. Meanwhile, zanzalintinib could earn approval by March of 2027.
The Motley Fool • Nov 16, 2026

Exelixis Has 2 Major Catalysts Coming by March 2027. Here's What Investors Should Watch.
Exelixis' cabozantinib, addressing various types of cancer, has driven tremendous growth over the past 10 years. The company is now betting on a next-generation candidate that's approaching the finish line.
The Motley Fool • Nov 13, 2026

Exelixis Bets on Zanza as Next Cancer Franchise as FDA Decision Nears
Exelixis NASDAQ: EXEL is working to build its next cancer drug franchise around zanzalintinib, or zanza, while continuing to grow its established CABO business, Chief Strategy Officer Andrew Peters said at a conference discussion with Guggenheim biotech analyst Michael Schmidt.
MarketBeat • Nov 11, 2026

Exelixis Nears FDA Decision, Key Kidney Cancer Data for Zanzalintinib
Exelixis NASDAQ: EXEL is preparing for a regulatory decision on its cancer drug candidate zanzalintinib and expects results from a kidney cancer study in the first quarter of next year, Chief Strategy Officer Andrew Peters said at an investor event.
MarketBeat • Nov 11, 2026

Exelixis, Inc. (EXEL) Presents at Stifel 2026 Healthcare Conference 2026 Transcript
Exelixis, Inc. (EXEL) Presents at Stifel 2026 Healthcare Conference 2026 Transcript
Seeking Alpha • Nov 11, 2026

Exelixis, Inc. (EXEL) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript
Exelixis, Inc. (EXEL) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript
Seeking Alpha • Nov 10, 2026

Here's Why Exelixis (EXEL) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks Investment Research • Nov 9, 2026

The Top 5 Biotech Stocks I'd Buy Right Now Without Any Hesitation
These five biotechs all have promising late-stage pipeline candidates. Existing products and new launches could power strong returns for all five over the medium term.
The Motley Fool • Nov 8, 2026

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in November:Guggenheim 3rd Annual Healthcare Innovation Conference: Exelixis is scheduled to present at 9:30 a.m. ET / 6:30 a.m. PT on Tuesday, November 10 in Boston.Stifel 2026 Healthcare Conference: Exelixis is scheduled to present at 1:20 p.m. ET / 10:20 a.m. PT on Wednesday, November 11 in New York City.UBS Global Bio.
Business Wire • Nov 3, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Exelixis Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.